Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 b/g alone or in combination with pembrolizumab: Initial results from dose escalation

被引：0

作者：

Starodub, Alexander

Powderly, John D.

Kim, Sung-Bae

Davar, Diwakar

Hill, Andrew Graham

Yeku, Oladapo O.

Gabrail, Nashat Y.

Krapp, Christian

Pihl, Susanne

Zhang, Ying

Slavsky, Sibel

Castro, Davis Y. Torrejon

Uyei, Anne

Singel, Stina Mui

Kwatra, Vineet

机构：

[1] Christ Hosp Hlth Network, Cincinnati, OH USA

[2] Carolina BioOncol Inst, Huntersville, NC USA

[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[4] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[5] Tasman Oncol Res, Southport, Qld, Australia

[6] Massachusetts Gen Hosp, Boston, MA 02114 USA

[7] Gabrail Canc Ctr, Canton, OH USA

[8] Ascendis Pharma, Copenhagen, Denmark

[9] Ascendis Pharma, Palo Alto, CA USA

[10] Ascendis Pharma Inc, Palo Alto, CA USA

[11] Canc Res South Australia, Adelaide, SA, Australia

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e14597

引用

页数：1